A nurse is collecting data from a client who has been taking carbamazepine. Which of the following is an adverse effect of carbamazepine and should be reported to the provider?

D. One of the primary requirements of the iPledge program for sexually active females of childbearing potential is the use of two forms of contraception simultaneously, beginning one month before starting isotretinoin therapy, throughout therapy, and for one month after discontinuation of therapy. This is to ensure effective contraception and prevent pregnancy due to the teratogenic effects of isotretinoin.
A. While mammograms are important screening tests for breast cancer, they are not a requirement of the iPledge program for female clients receiving isotretinoin.
B. Papanicolaou (Pap) tests, which screen for cervical cancer, are not a requirement of the iPledge program. However, sexually active females of childbearing potential must have monthly pregnancy tests and must agree to use two forms of contraception simultaneously during isotretinoin therapy.
C. There is no requirement for clients to take a daily supplement of vitamin A prior to initiating isotretinoin therapy as part of the iPledge program.

D. The absence of headache indicates a therapeutic response to sumatriptan. Sumatriptan is specifically indicated for the acute treatment of migraine attacks with or without aura and the acute treatment of cluster headache episodes. The absence of headache indicates that sumatriptan has effectively relieved the headache symptoms.
A. Improved mood is not a direct therapeutic response to sumatriptan. While relieving headache pain may contribute to an improved mood, sumatriptan primarily targets headache symptoms rather than mood regulation.
B. Increased bone mass is not a therapeutic response to sumatriptan. Sumatriptan does not affect bone metabolism or bone mass. Therefore, changes in bone mass would not be related to sumatriptan therapy.
C. Sumatriptan is not used in the management of chest pain.